Yoda Pharmaceuticals Inc.

7829 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

52.00TWD+3.05 (+6.23%)

Price History

Full chart

Market Stats

Previous Close48.95

Open47.20

Day Range47.20 – 52.00

52-Week Range36.20 – 62.20

Volume37.74K

Market Cap5.87B

P/E (TTM)0.00

Forward P/E0.00

EPS-4.27

Dividend Yield0.00%

50-Day Avg47.89

200-Day Avg48.58

About

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company's flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson"s disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. was incorporated in 2019 and is based in Grand Cayman, the Cayman Islands.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOProf. Yufeng Tseng
HeadquartersThe Grand Pavilion Commercial Centre, Grand Cayman, Cayman Islands, KY1- 1208, Taiwan
Websitehttps://yodapharma.com

Leadership

Prof. Yufeng TsengFounder, CEO & Director
Prof. Wen-Sung LaiFounder & Director
Zhi Qiang ShenAccounting Supervisor

Financials

Income Statement

Currency: TWD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	-	-
Operating Income	-45.14M	-89.88M	-221.91M	-391.87M
EBITDA	-43.08M	-84.46M	-190.84M	-404.73M
Net Income	-43.85M	-85.32M	-192.19M	-407.22M
R&D	42.29M	82.00M	204.35M	353.07M
Interest Expense	14.00K	22.00K	0	26.00K

Balance Sheet

Currency: TWD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	30.36M	358.56M	644.45M	1.02B
Total Liabilities	12.60M	22.83M	18.36M	33.46M
Total Equity	17.76M	335.74M	626.09M	984.02M
Cash	19.20M	34.77M	569.11M	325.38M

Cash Flow

Currency: TWD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-44.24M	-76.71M	-187.43M	-353.39M
Capital Expenditure	0	1.30M	2.32M	389.00K
Free Cash Flow	-44.24M	-78.01M	-189.75M	-353.78M
FCF to OCF	100.00%	101.69%	101.24%	100.11%

Key Statistics & Ratios

Market Cap5.87B

Enterprise Value4.77B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book5.48

EPS-4.27

Book Value10.73

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-381.91M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-48.22%

Return on Assets-30.44%

Shares Outstanding99.39M

Shares Float67.96M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%